PerkinElmer announced this week its documentation, workflow and decision-making Signals informatics platform is being expanded to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with life science software company, Insightful Science.
With the collaboration, pharmaceutical and academic research teams can bring together the power of the PerkinElmer Signals platform with solutions from Insightful Science’s Bioinformatics division. This includes the SnapGene and Geneious Prime software offerings that help molecular biologists design and execute DNA construct design, molecular cloning and other kinds of molecular biology research. The integration will give scientists the ability to access and compare data across experiments and instruments and collaborate more intuitively. They can also replicate assays and experiments instantly, leading to faster time-to-result and more informed decision making on drug and vaccine targets.
“There is a limited availability of IT tools in the biologics space,” said PerkinElmer, Informatics VP and GM Kevin Willoe. “Through our collaboration with Insightful Science, we’re able to provide enhanced informatics capabilities to scientists doing vital biologics and vaccine research. This will help significantly reduce cycle times for researchers and aid them in making data-driven decisions faster and more accurately – important capabilities when fighting foes like cancer, cardio, neurological and viral diseases.”
“The integration of best-in-class scientific software with cloud-based data platforms is increasingly essential for modern pharmaceutical and biotech enterprises to streamline research and ensure the integrity of valuable data,” added Bioinformatics at Insightful Science CEO Brett Ammundsen. “The combination of SnapGene and Geneious Prime software with the PerkinElmer Signals platform powerfully enhances research workflows and enriches collaboration. Ultimately this will better connect scientists to their ideas and data, so they can focus on producing life-changing outcomes.”